CN111909243B - Antibacterial peptide, antibacterial and itching-relieving pharmaceutical composition and application - Google Patents
Antibacterial peptide, antibacterial and itching-relieving pharmaceutical composition and application Download PDFInfo
- Publication number
- CN111909243B CN111909243B CN202010774440.8A CN202010774440A CN111909243B CN 111909243 B CN111909243 B CN 111909243B CN 202010774440 A CN202010774440 A CN 202010774440A CN 111909243 B CN111909243 B CN 111909243B
- Authority
- CN
- China
- Prior art keywords
- antibacterial
- pharmaceutical composition
- antibacterial peptide
- peptide
- gram
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention discloses an antibacterial peptide, which belongs to the field of biological medicine and has the amino acid sequence shown in SEQ ID NO: 1, has a theoretical molecular weight of 1758.14, a theoretical isoelectric point of 12.01, and is a basic cationic peptide. The invention also discloses a pharmaceutical composition which contains the antibacterial peptide, dyclonine, triamcinolone acetonide and menthol. The antibacterial peptide provided by the invention has a wide antibacterial spectrum, has an inhibiting effect on most gram-positive bacteria and gram-negative bacteria, and has high inhibiting activity. The antibacterial peptide has the advantages of small molecular weight, convenient artificial synthesis, low production cost and higher safety, and is suitable for large-scale mass production and application.
Description
Technical Field
The invention belongs to the field of biological medicines, and particularly relates to an antibacterial peptide, an antibacterial and antipruritic pharmaceutical composition and application thereof.
Background
Infection by pathogenic microorganisms poses a significant threat to the health of humans and animals, and is often accompanied by symptoms such as pain or itching, which can protect humans and/or other mammals from danger. Inflammation is often accompanied after infection of a human or an animal by pathogenic microorganisms, itching and pain are not only symptoms of inflammation, but also sensory neurons actively participate in detection of pathogens and regulation of inflammation by the host, and can remove pathogens by mediating host defense, and these neuron-microorganism and nerve-immune interactions may play a key role in host-pathogen defense.
Investigation of the main pathogenic bacterial, fungal and parasitic pathogens has shown that some infections are characterized by pain, some are characterized by itching, or both. Nociceptors and pruriceptors may have different pathogenic receptors, for example, bacterial pathogens may specifically bind to nociceptors to produce pain, parasites to specific receptors to produce itch, invasion of pathogens into the epidermis to produce itch, and infection of deeper tissues or internal organs to produce pain.
The development of a compound preparation with double functions of resisting microorganisms and relieving itching is an effective way for solving the problem of itching caused by the infection of pathogenic microorganisms. The antibacterial peptide is a polypeptide with antibacterial activity separated and obtained from microorganisms, animals and plants, and is widely applied to the fields of antibiotic preparation or food preservation and the like at present. It is believed that antimicrobial peptides kill bacteria by disrupting the integrity of the cell membrane, which results in the loss of the intracellular and extracellular barriers. However, with the emergence of drug-resistant pathogenic strains, the drug resistance problem of pathogenic bacteria has increasingly threatened the health of people, and the search for a brand-new type of antibiotic is an effective way to solve the drug resistance problem, and the antibacterial peptide has a wide application prospect in the medical industry because of high antibacterial activity, wide antibacterial spectrum, multiple types, wide selectable range and the like.
Disclosure of Invention
The first purpose of the invention is to provide a new antibacterial peptide, which aims to overcome the drug resistance of pathogenic bacteria and has the advantages of wide antibacterial spectrum, high antibacterial activity, small molecular weight, easy synthesis and the like.
The amino acid sequence of the antibacterial peptide provided by the invention is as follows: KATIFGLAAWALLRRA (SEQ ID NO: 1) has a theoretical molecular weight of 1758.14, a theoretical isoelectric point of 12.01, and is a basic cationic peptide.
The antibacterial peptide can be prepared by a conventional solid phase synthesis method and purified by a reverse high performance liquid chromatography method.
The second purpose of the invention is to provide the application of the antibacterial peptide in preparing antibacterial agents. In-vitro antibacterial activity tests show that the antibacterial peptide has good inhibitory activity on gram-positive bacteria (staphylococcus aureus, staphylococcus epidermidis, bacillus subtilis) and gram-negative bacteria (escherichia coli, klebsiella pneumoniae, pseudomonas aeruginosa and acinetobacter baumannii), wherein the MIC value of the antibacterial peptide on the gram-positive bacteria is less than or equal to 16 mu mol/L, the MIC value of the antibacterial peptide on the gram-negative bacteria is less than or equal to 32 mu mol/L, and the antibacterial peptide still cannot cause obvious hemolysis on human erythrocytes at the final concentration of 32 mu mol/L, so the antibacterial peptide can be safely applied to human bodies as an antibiotic and can also be applied to preparation of in-vitro antibacterial agents, such as food preservation or preservatives.
It is a third object of the present invention to provide an antibacterial agent whose active ingredient can be used either alone or in combination with other antibacterial agents such as antibiotics, antiseptics, etc. for application to the human body or in vitro.
The fourth purpose of the invention is to provide a pharmaceutical composition, which contains the antibacterial peptide, dyclonine, triamcinolone acetonide and menthol. The pharmaceutical composition has dual functions of antibiosis and itching relieving, so that the pharmaceutical composition can be better applied to the treatment of related diseases caused by microbial infection.
Preferably, the mass ratio of the antibacterial peptide, the dyclonine, the triamcinolone acetonide and the menthol is 2-5: 0.5-1: 0.5-1: 0.5-1.
Further preferably, the pharmaceutical composition further comprises pharmaceutically acceptable excipients, and the pharmaceutical composition can be prepared into any dosage form suitable for clinical use by utilizing the excipients, wherein the dosage forms include but are not limited to injections, tablets, powders, granules, capsules, oral liquids, ointments, creams and gels.
The fifth purpose of the invention is to provide the application of the pharmaceutical composition in preparing antibacterial and antipruritic medicines.
The invention has the beneficial effects that:
the antibacterial peptide provided by the invention has a wide antibacterial spectrum, has an inhibiting effect on most gram-positive bacteria and gram-negative bacteria, and has high inhibiting activity. The antibacterial peptide has the advantages of small molecular weight, convenient artificial synthesis, low production cost and higher safety, and is suitable for large-scale industrial production and application.
The pharmaceutical composition provided by the invention has dual functions of antibiosis and itching relieving, has definite curative effect and less toxic and side effects, and has the potential of being subsequently developed as a new drug product.
Drawings
FIG. 1 is an HPLC chromatogram of antimicrobial peptide.
FIG. 2 shows the results of the measurement of hemolytic activity of antimicrobial peptides.
FIG. 3 shows the result of the measurement of the antibacterial activity of the pharmaceutical composition (gel).
FIG. 4 shows the result of the measurement of antipruritic effect of the pharmaceutical composition (gel).
Detailed Description
The present invention is further described in detail below with reference to specific examples for better understanding of the present invention, but those skilled in the art will appreciate that the following examples are not intended to limit the scope of the present invention and that any changes and modifications made based on the present invention are within the scope of the present invention.
EXAMPLE 1 preparation of antimicrobial peptides
In the synthesis of the polypeptide sequence, 9-Fluorenylmethyloxycarbonyl (FMOC) is used for protecting an amino end group, 4-methyl-benzhydrylamine resin (4-methyl-benzhydrylamine resin HCl, MBHA resin) is selected as a solid phase carrier, HOBt/DCC is selected as a condensing agent, and a peptide chain is extended from a carboxyl terminal to an amino terminal. It was cleaved from the MBHA resin with a mixture (mass%) of 92% trifluoroacetic acid, 4% water and 4% Triisopropylsilane (TIA). After repeated several precipitations with diethyl ether, purification was carried out by preparative RP-HPLC. Columns (250 mm. times.20 mm, 5 μm) were prepared using C18 reversed phase; mobile phase: 1.5 per mill trifluoroacetic acid and 0-60 percent (volume percentage) acetonitrile are taken as mobile phases, and gradient elution is carried out at the flow rate of 2 mL/min. RP-HPLC detection shows that Retention Time (RT) is 10.8min, and the purity is calculated by peak area normalization method>95% (fig. 1), and is ready for use after lyophilization. Identified by ESI-QTOF-MS, M/z 880.34[ M +2H ]]2+，m/z 586.68[M+3H]3+，m/z 440.93[M+4H]4+The molecular weight of the polypeptide is consistent with the corresponding theoretical molecular weight of the polypeptide to be prepared, and the amino acid sequence is as follows: KATIFGLAAWALLRRA are provided.
Example 2 in vitro antimicrobial Activity assay of antimicrobial peptides
The gram-positive bacteria to be detected comprises staphylococcus aureus, staphylococcus epidermidis and bacillus subtilis; gram-negative bacteria to be detected comprise escherichia coli, klebsiella pneumoniae, pseudomonas aeruginosa and acinetobacter baumannii, and the strains are purchased from China Center for Type Culture Collection (CCTCC). The Minimum Inhibitory Concentration (MIC) is determined by adopting a multiple dilution method, and the in vitro antibacterial activity of the polypeptide with the antibacterial function is characterized by the MIC value.
The specific method comprises the following steps:
the strains to be tested are respectively inoculated in a sterilized Luria-Bertani (LB) solid culture medium plate by a three-region streaking method and are inversely cultured for 8 to 10 hours in a constant temperature incubator at 37 ℃. Single colonies picked by the inoculating loop are respectively transferred into a sterilized liquid LB culture medium and are shake-cultured to the logarithmic phase under the conditions of 37 ℃ and 150 rpm. Measuring absorbance (OD) of the bacteria solution at 630nm wavelength with enzyme-labeling instrument630) According to 1OD 1 × 109CFU/mL conversion, the standard strain was diluted to (1-2). times.10 with the culture medium5CFU/mL。
Firstly, 100 mu L of sterilized LB culture medium is added into a sterile 96-well plate; then adding 100 mu L of polypeptide solution dissolved by sterilized LB culture medium and having the concentration of 128 mu mol/L into the 1 st hole, uniformly mixing, adding 100 mu L into the 2 nd hole, sucking 100 mu L from the 6 th hole, discarding, and sequentially diluting twice; finally, 1X 10 concentration was added to each well5And (5) mixing the diluted bacterial liquid 100 mu L in CFU/mL uniformly. Each empty with no added polypeptide served as a negative control.
Each of the above groups was shake-cultured at 37 ℃ for about 24 hours, and the absorbance at a wavelength of 630nm was measured. No detectable bacterial growth (OD) was obtained at the Minimum Inhibitory Concentration (MIC)630≦ 0.05) for the lowest final concentration of polypeptide in the wells. The bacteria liquid in the negative control hole is turbid, and the absorbance OD at 630nm is630Is greater than 3. The polypeptide with antibacterial function described in the patentThe results of in vitro antibacterial activity of (b) are shown in table 1.
TABLE 1 antibacterial Activity of antibacterial peptides
As can be seen from the results in table 1, the antibacterial peptides according to the present invention exhibited superior antibacterial activity. The inhibitor has good inhibitory activity to gram-positive bacteria and gram-negative bacteria, and the MIC value to the gram-positive bacteria is less than or equal to 16 mu mol/L, and the MIC value to the gram-negative bacteria is less than or equal to 32 mu mol/L.
EXAMPLE 3 determination of hemolytic Activity of antimicrobial peptides
Fresh blood was obtained from a healthy donor, human red blood cells were separated and suspended, and hemolytic activity of the antimicrobial peptide was measured using sterilized physiological saline as a negative control and 1% Triton X-100 as a positive control.
The method comprises the following specific steps: collecting whole blood with EDTA anticoagulation tube, slightly inverting to fully anticoagulate blood, centrifuging at room temperature of 400rpm for 6min, discarding upper layer plasma and retaining lower layer red blood cells; adding 4 times volume of sterilized normal saline, slightly inverting to make the centrifuge tube suspend the bottom red blood cells, centrifuging at room temperature at 400rpm for 6min, discarding the supernatant, retaining the precipitated red blood cells, repeating the operation for 3 times until the supernatant is colorless; preparing erythrocyte into 2% (v/v) cell suspension by using sterilized normal saline; dissolving the polypeptide with sterilized normal saline to obtain solutions with concentrations of 64. mu. mol/L, 32. mu. mol/L, 16. mu. mol/L, 8. mu. mol/L, 4. mu. mol/L, 2. mu. mol/L and 1. mu. mol/L; mixing 100. mu.L of the polypeptide solution and 100. mu.L of the erythrocyte suspension and adding to a 96-well plate, the final concentrations of the polypeptide being 32. mu. mol/L, 16. mu. mol/L, 8. mu. mol/L, 4. mu. mol/L, 2. mu. mol/L, 1. mu. mol/L, and 0.5. mu. mol/L, respectively; the negative control group is red blood cells suspended by sterilized physiological salt, and the positive control group is red blood cells suspended by sterilized physiological salt containing 1% TritonX-100; putting the sample into a constant temperature shaking table, and incubating for 1 hour at the temperature of 37 ℃ and at the rpm of 80-100; the samples were centrifuged at 3500rpm for 5min at room temperature, and 100. mu.L of supernatant per well was transferred to another 96 well plate; using full-wavelength enzyme labelsThe absorbance at 490nm was measured and the percentage of hemolysis was calculated by the following formula, where H is the absorbance at 490 nm: hemolysis rate (%) - (H)sample-Hnegative)/(Hpositive-Hnegative) X 100%, as shown in FIG. 2.
The results show that no significant hemolysis (hemolysis rate < 15%) is observed at final concentrations of up to 32. mu. mol/L of the antimicrobial peptide of the present invention.
EXAMPLE 4 tablets
Antibacterial peptide: the compound of dyclonine: triamcinolone acetonide: menthol-2.5: 1: 1: 1
Mixing antibacterial peptide 0.025g, dyclonine 0.01, triamcinolone acetonide 0.01, menthol 0.01g, starch 1.2g, and dextrin 1.2g, granulating with 35% medicinal grade polyvinylpyrrolidone (PVP) as binder, grading, and tabletting to obtain compound tablet.
EXAMPLE 5 gelling agent
Antibacterial peptide: the compound of dyclonine: triamcinolone acetonide: menthol-5: 1: 1: 1
And (3) taking 12mL of distilled water, scattering carbomer on the liquid surface, and stirring to fully swell the carbomer. Adding propylene glycol, mixing, and adding triethanolamine under stirring to obtain gel matrix; 0.05g of antibacterial peptide, 0.01g of dyclonine, 0.01g of triamcinolone acetonide and 0.01g of menthol are dissolved in 0.01M PBS buffer (pH 7.4), and slowly added to the gel matrix under continuous stirring. And finally, adding the residual distilled water to prepare 20g of the antibacterial and itching-relieving compound gel preparation.
Example 6 lyophilized powder for injection
Antibacterial peptide: the compound of dyclonine: triamcinolone acetonide: menthol-5: 1: 0.5: 0.5
Taking 0.5g of antibacterial peptide, 0.1g of dyclonine, 0.05g of triamcinolone acetonide, 0.05g of menthol and 10g of mannitol, putting the antibacterial peptide into a container, adding a proper amount of PBS (0.15M, pH7.4) for dissolving, adding injection water to 100mL, shaking up, adding 2-3 g of needle activated carbon, stirring for 25-45 minutes at room temperature, carrying out rough filtration, filtering and sterilizing by using a 0.22 mu M filter membrane, subpackaging, wherein 1mL of each bottle is obtained, cooling 8-10 ℃ per minute, cooling to-45 ℃, maintaining for 3.0 hours by adopting a quick freezing method, vacuumizing, slowly heating at a vacuum state, heating at a speed of 2-6 ℃ per hour, stopping heating when the temperature is raised to 28 ℃, taking out after the temperature is close to the room temperature, and covering and sealing to obtain the freeze-dried powder injection.
EXAMPLE 7 determination of antibacterial Activity of Compound preparation
Selecting gram-positive staphylococcus aureus ATCC 25923 as a strain to be detected. The strains to be tested are respectively inoculated in a sterilized Luria-Bertani (LB) solid culture medium plate by a three-region streaking method and are inversely cultured for 8 to 10 hours in a constant temperature incubator at 37 ℃. Single colonies picked with the inoculating loop were transferred to sterilized liquid LB medium, respectively, and cultured to logarithmic phase at 37 ℃ under 150rpm with shaking. Measuring absorbance (OD) of the bacteria solution at 630nm wavelength with enzyme-labeling instrument630) According to 1OD 1 × 109CFU/mL conversion, the standard strains were diluted to (1-2). times.10 in liquid medium6CFU/mL is ready for use.
Preparing solid LB culture medium, sterilizing, cooling to 50-60 deg.C, adding 1mL bacterial liquid per 10mL culture medium, and adding bacteria solution with concentration of (1-2) × 106And (3) uniformly mixing the CFU/mL bacterial solution, and immediately preparing a solid culture medium plate containing the strain to be detected. Divided into three groups of 6 plates; the first group is a solid LB culture medium plate containing the strain to be detected without any treatment; a second group of gel matrices (i.e. without the polypeptide, dyclonine, triamcinolone acetonide, menthol) applied to the plates; third group the gel prepared in example 5 was spread on a plate. The three groups of 18 plates are put into an incubator at 37 ℃ for 12-16 hours. The number of colonies on each plate was recorded and the results are shown in FIG. 3.
The results show that single colony grows on the first group of plates and the second group of plates, the colony number between the two groups of plates has no obvious difference, and the colony number growing on the third group of plates (the compound gel containing the active ingredients) is far less than that of the first group of plates and the second group of plates, so that the compound preparation has obvious antibacterial effect.
EXAMPLE 8 antipruritic Effect test of Compound preparation
Animal experiments were approved by the animal protection and use committee (ethics), and 2 to 3 month old male (20-30g) C57BL/6 mice were used as study subjects. After a period of acclimation, an appropriate amount of an itch-causing agent (histamine) was injected subcutaneously into the neck, and scratching was observed for 30 minutes. The number of scratching behaviors of the mouse hind paw to the area around the injection site was recorded. Divided into three groups of 6 mice each; the first group injected the mice with a suitable amount of the itch-causing agent histamine only through the subcutaneous neck; the second group evenly coated the gel matrix (i.e. without the polypeptide, dyclonine, triamcinolone acetonide, menthol) at the injection site within a radius of 1cm immediately after the mice were injected with a suitable amount of the itch-causing agent histamine subcutaneously into the neck; the third group evenly spread the gel preparation prepared in example 5 over a radius of 1cm at the injection site immediately after injecting a proper amount of histamine, an itch inducing agent, into the subcutaneous neck of the mouse, and the result is shown in fig. 4.
The result shows that the scratching times of the mice in the first group and the second group are not obviously different, and the matrix of the compound gel has no antipruritic activity; and the scratching times of the third group (the compound gel containing the active ingredients) are obviously lower than those of the first group and the second group, which indicates that the compound preparation has obvious itching relieving effect.
Sequence listing
<110> Wuhan compactable surge Biotechnology GmbH
Shen Bingzheng
<120> antibacterial peptide, antibacterial and antipruritic pharmaceutical composition and application
<160> 1
<170> SIPOSequenceListing 1.0
<210> 1
<211> 16
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 1
Lys Ala Thr Ile Phe Gly Leu Ala Ala Trp Ala Leu Leu Arg Arg Ala
1 5 10 15
Claims (9)
1. An antibacterial peptide, wherein the amino acid sequence of the antibacterial peptide is shown in SEQ ID NO: 1, has a theoretical molecular weight of 1758.14, a theoretical isoelectric point of 12.01, and is a basic cationic peptide.
2. Use of the antimicrobial peptide of claim 1 for the preparation of an antimicrobial agent against gram-positive and gram-negative bacteria.
3. Use according to claim 2, characterized in that: the antibacterial agent is an agent for resisting staphylococcus aureus, staphylococcus epidermidis, bacillus subtilis, escherichia coli, klebsiella pneumoniae, pseudomonas aeruginosa and acinetobacter baumannii.
4. An antibacterial agent comprising the antibacterial peptide according to claim 1 as an active ingredient.
5. A pharmaceutical composition characterized by: comprising the antibacterial peptide according to claim 1, dyclonine, triamcinolone acetonide and menthol.
6. The pharmaceutical composition of claim 5, wherein: the mass ratio of the antibacterial peptide to the dyclonine to the triamcinolone acetonide to the menthol is 2-5: 0.5-1: 0.5-1: 0.5-1.
7. The pharmaceutical composition of claim 5, wherein: the pharmaceutical composition also comprises pharmaceutically acceptable auxiliary materials.
8. The pharmaceutical composition of claim 7, wherein: the pharmaceutical composition is injection, tablet, powder, granule, capsule, oral liquid, ointment, cream, and gel.
9. Use of a pharmaceutical composition according to any one of claims 5 to 8 for the manufacture of a medicament for antibacterial antipruritic treatment.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010774440.8A CN111909243B (en) | 2020-08-04 | 2020-08-04 | Antibacterial peptide, antibacterial and itching-relieving pharmaceutical composition and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010774440.8A CN111909243B (en) | 2020-08-04 | 2020-08-04 | Antibacterial peptide, antibacterial and itching-relieving pharmaceutical composition and application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111909243A CN111909243A (en) | 2020-11-10 |
| CN111909243B true CN111909243B (en) | 2022-01-18 |
Family
ID=73287086
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010774440.8A Active CN111909243B (en) | 2020-08-04 | 2020-08-04 | Antibacterial peptide, antibacterial and itching-relieving pharmaceutical composition and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111909243B (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103314005A (en) * | 2011-03-25 | 2013-09-18 | 利普泰股份公司 | Peptides useful in the treatment and/or care of the skin and/or mucous membranes and their use in cosmetic or pharmaceutical compositions |
| CN103951732A (en) * | 2014-05-08 | 2014-07-30 | 南方医科大学 | Antibacterial peptide |
| EP3434287A1 (en) * | 2017-07-25 | 2019-01-30 | Arta Peptidion S.r.l.s. | Short and ultra-short antimicrobial lipopeptides and use thereof |
| CN110066317A (en) * | 2019-04-19 | 2019-07-30 | 武汉大学 | A kind of the dimer polypeptide and its application difunctional with antibacterial and immunological regulation |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2661634C (en) * | 2006-09-06 | 2017-03-28 | The Regents Of The University Of California | Selectively targeted antimicrobial peptides and the use thereof |
| CN105294838B (en) * | 2015-09-22 | 2018-07-03 | 徐州市玛泰生物科技有限公司 | A kind of antibacterial peptide and its application |
| KR101847051B1 (en) * | 2016-04-26 | 2018-04-09 | 한국외국어대학교 연구산학협력단 | Antibiotic peptides having an antibiotics and comprising antibiotic composition thereof |
-
2020
- 2020-08-04 CN CN202010774440.8A patent/CN111909243B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103314005A (en) * | 2011-03-25 | 2013-09-18 | 利普泰股份公司 | Peptides useful in the treatment and/or care of the skin and/or mucous membranes and their use in cosmetic or pharmaceutical compositions |
| CN103951732A (en) * | 2014-05-08 | 2014-07-30 | 南方医科大学 | Antibacterial peptide |
| EP3434287A1 (en) * | 2017-07-25 | 2019-01-30 | Arta Peptidion S.r.l.s. | Short and ultra-short antimicrobial lipopeptides and use thereof |
| CN110066317A (en) * | 2019-04-19 | 2019-07-30 | 武汉大学 | A kind of the dimer polypeptide and its application difunctional with antibacterial and immunological regulation |
Non-Patent Citations (3)
| Title |
|---|
| "NMR structures and mutational analysis of the two peptides constituting the bacteriocin plantaricin S ";Bie ekblad et al.;《Scientific Reports》;20190220;第9卷;第1-10页 * |
| "Structure-Activity Relationships of an Antimicrobial Peptide Plantaricin S from Two-Peptide Class IIb Bacteriocins";Wael Soliman et al.;《Journal of Medicinal Chemistry》;20110309;第54卷;第2399-2408页 * |
| "真菌来源的抗微生物多肽研究进展";沈秉正 等;《广东药科大学学报》;20200430;第36卷(第2期);第303-309页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN111909243A (en) | 2020-11-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9273095B2 (en) | Antibiotic peptide and preparation method therefor and application therefor | |
| US12115209B2 (en) | ROMO1-derived antimicrobial peptides including lysine substitution and variants thereof | |
| KR101896927B1 (en) | An anti-microbial peptide, Protaetiamycine 1 isolated from Protaetia brevitarsis seulensis and its synthetic composition | |
| KR101700603B1 (en) | An anti-microbial peptide, Periplanetasin-1 isolated from Periplaneta americana and its synthetic composition | |
| KR20180002618A (en) | Antibacterial peptides and methods for their use | |
| KR101889396B1 (en) | An anti-microbial peptide, Protaetiamycine 2 isolated from Protaetia brevitarsis seulensis and its synthetic composition | |
| KR20160055343A (en) | An anti-microbial peptide Scolopendrasin-7 isolated from the Scolopendra subspinipes mutilans and its synthetic peptide | |
| KR101444257B1 (en) | A new scolopendrasin ii peptide isolated from the scolopendra subsinipes and its synthetic composition | |
| KR101953828B1 (en) | An anti-microbial peptide, Teleogryllusine 1 isolated from Teleogryllus emma and its synthetic composition | |
| KR101667535B1 (en) | An anti-microbial peptide Scolopendrasin-6 isolated from the Scolopendra subspinipes mutilans and its synthetic peptide | |
| KR101740551B1 (en) | An anti-microbial peptide, Oxyasin-2 isolated from Oxya chinensis sinuosa and its synthetic composition | |
| KR101743113B1 (en) | An anti-microbial peptide, Oxyasin-1 isolated from Oxya chinensis sinuosa and its synthetic composition | |
| CN114209808A (en) | Application of polypeptide RK12 in preparation of medicine for treating acne | |
| JP3361830B2 (en) | Antimicrobial composition and drug containing the same as active ingredient | |
| KR101953834B1 (en) | An anti-microbial peptide, Teleogryllusine 2 isolated from Teleogryllus emma and its synthetic composition | |
| KR101444256B1 (en) | A new scolopendrasin iii peptide isolated from the scolopendra subsinipes and its synthetic composition | |
| CN111909243B (en) | Antibacterial peptide, antibacterial and itching-relieving pharmaceutical composition and application | |
| CN110066317B (en) | Dimer polypeptide with antibacterial and immunoregulation double functions and application thereof | |
| CN107794232B (en) | Streptococcus antagonizing growth of propionibacterium acnes and gram-positive bacteria and metabolites thereof | |
| CN112110993B (en) | Chemically synthesized dimer polypeptide with antibacterial and antifungal effects, and preparation method and application thereof | |
| CN103974713A (en) | Antimicrobial peptides for treatment of infectious diseases | |
| KR101825952B1 (en) | An anti-microbial peptide, Oxyasin-3 isolated from Oxya chinensis sinuosa and its synthetic composition | |
| CN110283237B (en) | Peptide mimic with antimicrobial function from pathogenic fungi, and preparation method, composition and application thereof | |
| KR101851134B1 (en) | An anti-microbial peptide, Periplanetasin-6 isolated from Periplaneta americana and its synthetic composition | |
| KR101889404B1 (en) | An anti-microbial peptide, Periplanetasin-5 isolated from Periplaneta americana and its synthetic composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20211228 Address after: 102627 604, floor 6, building 7, yard 50, Chunhe Road, Daxing District, Beijing Applicant after: Likang Rongjian (Beijing) Biomedical Technology Co.,Ltd. Address before: 430000 No. 666 High-tech Avenue, Donghu New Technology Development Zone, Wuhan City, Hubei Province Applicant before: Wuhan Kangmat Biotechnology Co.,Ltd. Applicant before: Shen Bingzheng |
|
| TA01 | Transfer of patent application right | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |